Bright Minds Biosciences (DRUG) Cash from Operations (2020 - 2026)

Bright Minds Biosciences' Cash from Operations history runs 7 years deep, the most recent figure standing at 6742308.75 for Q1 2026.

• Quarterly Cash from Operations fell 498.9% year-over-year to 6742308.75 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 20020782.59 (down 9572.95% YoY) and the FY2025 annual result came in at 6315634.6, down 365.66% from the prior year.
• Cash from Operations was 6742308.75 for Q1 2026 at Bright Minds Biosciences, down from 4170502.83 in the prior quarter.
• Across five years, Cash from Operations topped out at 2878012.84 in Q1 2022 and bottomed at 19203648.9 in Q3 2022.
• A 5-year average of 2233233.59 and a median of 597467.18 in 2024 frame the typical range for Cash from Operations.
• Peak annual rise in Cash from Operations reached 182.9% in 2025, while the deepest fall reached 4562.31% in 2025.
• Bright Minds Biosciences' Cash from Operations stood at 1962334.99 in 2022, then tumbled by 69.23% to 603852.11 in 2023, then jumped by 77.16% to 1069760.66 in 2024, then tumbled by 489.85% to 4170502.83 in 2025, then plunged by 61.67% to 6742308.75 in 2026.
• Business Quant data shows DRUG's Cash from Operations at 6742308.75 in Q1 2026, 4170502.83 in Q4 2025, and 921379.0 in Q3 2025.